Vista Pharmaceuticals Ltd (VISTAPH) — shareholding pattern, promoter holding, financials and share price
About Vista Pharmaceuticals Ltd (VISTAPH)
Vista Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as VISTAPH and on the BSE under scrip code 524711. Its ISIN is INE427C01021.
Incorporated in 1992, Vista Pharmaceuticals Ltd manufactures and sells pharmaceutical, medical and veterinary preparations [1]
Vista Pharmaceuticals Limited formulates pharmaceutical products, primarily in therapeutic areas like gastrointestinal, pain management, and anti-infection drugs, targeting common ailments.
The company was the first Indian firm to receive USFDA approval for producing both OTC and prescription drugs for the US market in 1994.
Listed peers in Pharmaceuticals: Vivimed Labs Ltd, Shelter Pharma Ltd, Mangalam Drugs and Organics Ltd, ANG Lifesciences India Ltd, Rajnish Wellness Ltd, Sandu Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹7.28 a share on 10 Jul 2026, Vista Pharmaceuticals Ltd (VISTAPH) was valued at a price-to-earnings ratio of -3.72x against an industry P/E of 36.41x and a price-to-book of 0.99x on a book value of ₹7.38 per share as of Mar 2025. Solomo computes return on equity of -26.55% and return on capital employed of -28.49% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -3.72x
- Industry P/E
- 36.41x
- P/B
- 0.99x
- EPS (TTM)
- ₹-1.96
- Book value / share
- ₹7.38
- ROE
- -26.55%
- ROCE
- -28.49%
- ROA
- -20%
- Debt / equity
- 0.16x
- Dividend yield
- 0%
- EBITDA margin
- -265%
- 52-week range
- ₹5.71 – ₹11.69
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Vista Pharmaceuticals Ltd (VISTAPH) reported revenue of ₹5 crore, net profit of ₹-12 crore and earnings per share of ₹-1.96. That compares with revenue of ₹10 crore and net profit of ₹-5 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, net profit ₹-5.86 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 0 | 1 | 10 | 10 | 5 |
| Net profit (₹ cr) | -1 | -6 | -5 | -5 | -12 |
| EPS (₹) | -0.24 | -1.54 | -1.23 | -1.26 | -1.96 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -4.59% | -15.04% | 194.46% | -2.14% |
| Profit growth | - | - | - | -3.10% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 21.19% of Vista Pharmaceuticals Ltd (VISTAPH) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.02%. Market capitalisation was ₹45 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Murali Meraga 14.62%, Pavan Sathvik Gilaka 12.6%, Umakanth Katta 12.25%, SURESH GADALAY 4.64%, KAMAL GADALAY 3.03%, Deepthi Pachipala 2.44%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 21.19% | - | - | 0.02% | 78.81% |
| Mar 2026 | 21.19% | - | - | 0.02% | 78.81% |
| Dec 2025 | 21.19% | - | - | 0.02% | 78.81% |
| Sep 2025 | 21.19% | - | - | 0.02% | 78.81% |
| Jun 2025 | 21.19% | - | - | 0.02% | 78.81% |
| Mar 2025 | 21.19% | - | - | 0.02% | 78.81% |
| Dec 2024 | 21.19% | - | - | 0.02% | 78.81% |
| Sep 2024 | 21.19% | - | - | 0.02% | 78.81% |